This book provides an overview of the world market of therapeutic enzymes and enzyme inhibitors, rare diseases, orphan drugs, the costs of drug development and therapies, and enzymes in downstream processing of pharmaceuticals. It discusses carbonic anhydrase inhibitors and their multiple drug interactions, carboxylesterase inhibitors for pharmaceutical applications, employment of inhibitors for the treatment of neurodegenerative diseases, use of engineered proteins, bioactive peptides, and fibrinolytic enzymes for thrombolytic therapy, and enzymes important for the design and development of new drugs/drug metabolites such as aldehyde oxidases and cytochrome P450 enzymes and the role the latter play in vascular biology and pathophysiology. The treatment of cancer is explored in connection with enzymatic amino acid deprivation therapies and new drugs that act as chemical degraders of oncogenic proteins. The book also introduces the resistance mechanisms of cancer. Furthermore, it provides an insight into the relationship between pathological conditions of cardiovascular disease and oxidative stress. The text also focuses on the potential use of nanoparticles as carriers for enzymes with medical relevance, computer-aided drug design for the identification of multi-target directed ligands, and the development of improved therapeutics through a glycan-“designer” approach. It concludes with an introduction to the chemoenzymatic synthesis of drugs.
Table of Contents
Pharmaceuticals: Some General Aspects
Use of Enzymes in the Downstream Processing of Biopharmaceuticals
Duarte Miguel F. T. Prazeres
Therapeutic Use of Carbonic Anhydrase Inhibitors and Their Multiple Drug Interactions
Andrea Angeli and Claudiu T. Supuran
Fibrinolytic Enzymes for Thrombolytic Therapy
Swaroop S Kumar, Sabu Abdulhameed
Role of Engineered Proteins as Therapeutic Formulations
Khushboo Gulati and Krishna Mohan Poluri
Synthesis of bioactive peptides for pharmaceutical applications
Jaison Jeevanandam et al.
Cardiovascular Disease and Oxidative Stress
Marco Fernandes, Alisha Patel, and Holger Husi
Enzymatic Amino Acid Deprivation Therapies Targeting Cancer
Carla S. S. Teixeira et al.
Carboxylesterase inhibitors: Relevance for Pharmaceutical Applications
Li-Wei Zou abd Guang-Bo Ge
Molecular Aspects of the Activity and Inhibition of the FAD-containing Monoamine Oxidases
Rona R. Ramsay
Multifunctional Monoamine Oxidase and Cholinesterase Inhibitors for the Treatment of Alzheimer’s Disease
Ireen Denya, Sarel F. Malan, and Jacques Joubert
The Neurodegenerative Characteristics of Alzheimer’s Disease and Related Multi-Target Drug Design Studies
Hayrettin Ozan Gülcan, and Ilkay Erdogan Orhan
Aldehyde Oxidases as Enzymes in Phase I Drug Metabolism
Cristiano Mota et al.
Cytochrome P450 Enzymes for the Synthesis of Novel and Known Drugs and Drug Metabolites
Sanjana Haque et al.
Cytochromes P450, Cardiovascular Homeostasis and Disease
Chin Eng Ong et al.
Protein Degradation Inducers SNIPERs and PROTACs against Oncogenic Proteins
Norihito Shibata et al.
Resistance Mechanisms of Tumor Cells
Biocatalytic Nanoreactors for Medical Purposes
Oscar González-Davis, Kanchan Chauhan, and Rafael Vazquez-Duhalt
Computer-Aided Drug Design for the Identification of Multi-Target Directed Ligands (MTDLs) in Complex Diseases: An Overview
Pravin Ambure and Kunal Roy
The Development of Improved Therapeutics through a Glycan-‘Designer’ Approach
Natalia G. Bednarska
On Biocatalysis as Resourceful Methodology for Complex Syntheses: Selective Catalysis, Cascades, and Biosynthesis
Andreas Sebastian Klein, Thomas Classen, and Jörg Pietruszka
Peter Grunwald studied chemistry at the Universities of Saarbrücken and Hamburg, Germany. He graduated in the field of high-frequency spectroscopy and then became a staff member of the Institute of Physical Chemistry. After receiving his PhD in physical chemistry, he founded a biotechnology research group. He was appointed professor in 2001. His research interests focus on immobilized biocatalysts, kinetics of enzymes in organic solvents, and interactions between biocatalysts and heavy metal ions. Prof. Grunwald is also interested in chemical education, including curriculum development. He has authored a textbook on biochemistry and is an editorial board member of Catalysts.
“This book is an important addition to the literature in this field. It not only summarizes the importance of enzymes as targets for pharmaceutical drug research in the past but also shows that there is still enormous potential in the future. Motivated by Peter Grunwald, a large group of experts have shared their specialist knowledge. The book a treasure for anyone working or doing research in the field.”
Prof. Theo Dingermann, Goethe University, Germany
“This book represents an outstanding scientific work. It covers the state of the art, challenges, and key achievements of research focusing on the use of enzymes for therapeutic purposes. It discusses the fundamentals of enzyme function and its applications and shows how this fantastic research field has been explored in drug discovery and innovation for gaining a better understanding of enzymes and their use for a better quality of life.”
Prof. Cláudio Viegas Jr., Universidade Federal de Alfenas, Brazil